Illumina, Inc. vs Twist Bioscience Corp — how do they compare? Illumina, Inc. trades at $193.06 (market cap $29.12B), while Twist Bioscience Corp trades at $124 (market cap $7.72B). The key difference: Illumina, Inc. is far larger — about 3.8× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| ILMN | TWST | |
|---|---|---|
Market Cap | $29.12B | $7.72B |
Sector | Health | Health |
52-Week High | $205.10 | $124.88 |
52-Week Low | $91.00 | $24.16 |
Enterprise Value | $30.48B | $7.65B |
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →